No Detail Found!

Low Dose of Azithromycin Enhances the Anticancer Efficacy of Sorafenib in HepG2 Cell Line

Author(s)
Dabeeran Zehra Department of Pharmacology, Ziauddin University, Karachi, Pakistan
Zahida Memon Department of Pharmacology, Ziauddin University, Karachi, Pakistan
Shumaila Usman Department of Research, Ziauddin University, Karachi, Pakistan
Almas Jabeen Dr. Panjwani Centre for Molecular Medicine and Drug research, International Centre for Chemical and Biological Sciences, Karachi, Pakistan
Kauser Ismail Department of Pharmacology, Ziauddin University, Karachi, Pakistan
Rehan Ahmed Siddiqui Department of Research, Ziauddin University, Karachi, Pakistan
Abstract
Sorafenib, a multi kinase inhibitor, is the only FDA approved drug designed to target advanced hepatocellular carcinoma (HCC). However, unbearable side efects, insuficient efficacy and resistance mechanisms against this drug, generates necessity to develop novel therapeutic strategies and drugs. Recently macrolides have drawn attention of researchers in the treatment of cancer owing to their proposed chemotherapeutic role, based on the concept of repurposing, as they are well tolerated, less toxic and inexpensive. In this study we evaluated the combine effects of low dose of Azithromycin with Sorafenib in HepG2 cell line. Co-treatment of Sorafenib and Azithromycin showed enhanced inhibition of cell growth and suppressed the MAPK pathway associated with cellular proliferation, however the effects on cellular apoptosis were found to be insignificant.
Publication Details
Page(s) 1143-1152
Published Journal: Pakistan Journal of Zoology, Volume: 54, Issue: 3, Year: 2022

Request the full text from PASTIC

Keywords
azithromycin, Sorafenib, Anticancer efects, Drug repositioning, HepG2
0

Citations

0

Downloads

149

Views